Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
RCEL 
Avita Medical Ltd (RCEL)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
10/15/2025: RCEL (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
4 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $8.64
1 Year Target Price $8.64
| 3 | Strong Buy |
| 0 | Buy |
| 1 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -51.18% | Avg. Invested days 27 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 10/15/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 144.01M USD | Price to earnings Ratio - | 1Y Target Price 8.64 |
Price to earnings Ratio - | 1Y Target Price 8.64 | ||
Volume (30-day avg) 4 | Beta 1.64 | 52 Weeks Range 3.60 - 14.16 | Updated Date 10/15/2025 |
52 Weeks Range 3.60 - 14.16 | Updated Date 10/15/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.97 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -68.87% | Operating Margin (TTM) -60.53% |
Management Effectiveness
Return on Assets (TTM) -40.03% | Return on Equity (TTM) -935.73% |
Valuation
Trailing PE - | Forward PE 4.82 | Enterprise Value 176691568 | Price to Sales(TTM) 1.92 |
Enterprise Value 176691568 | Price to Sales(TTM) 1.92 | ||
Enterprise Value to Revenue 2.36 | Enterprise Value to EBITDA -6.17 | Shares Outstanding 27018934 | Shares Floating 26055411 |
Shares Outstanding 27018934 | Shares Floating 26055411 | ||
Percent Insiders 0.91 | Percent Institutions 29.22 |
Upturn AI SWOT
Avita Medical Ltd
Company Overview
History and Background
Avita Medical Ltd, formerly known as Clinical Cell Culture, was founded in 1993. It has focused on regenerative medicine solutions, particularly for burn care and skin restoration. Their key milestone is the development and commercialization of RECELL Autologous Cell Harvesting Device.
Core Business Areas
- Burn Care: The primary segment involves products for treating burn wounds, using autologous cell harvesting to regenerate skin tissue.
- Wound Reconstruction: Focuses on using the RECELL technology for reconstructive surgical procedures and other types of skin defects.
Leadership and Structure
Avita Medical Ltd has a board of directors overseeing the CEO and executive management team. The company is structured into functional departments like R&D, Marketing, Sales, and Operations.
Top Products and Market Share
Key Offerings
- RECELL Autologous Cell Harvesting Device: RECELL is Avita Medical's flagship product, used for rapid skin cell regeneration in burn and wound care. Estimated market share varies by geography and specific application, but Avita is considered a key player in spray-on skin technology. Competitors include Mallinckrodt, Integra LifeSciences, and Smith & Nephew who use other skin grafting and cell-based therapies.
Market Dynamics
Industry Overview
The regenerative medicine market, specifically for wound care and burn treatment, is experiencing growth driven by technological advancements and an aging population. The field is highly competitive, with companies developing innovative solutions for skin regeneration.
Positioning
Avita Medical is positioned as a leader in autologous cell harvesting technology, offering a unique and efficient solution for skin regeneration. Their RECELL device provides a competitive advantage in rapid treatment and reduced donor site requirements.
Total Addressable Market (TAM)
The global wound care market is expected to reach hundreds of millions of dollars and is growing. Avita Medical Ltd is positioned to capture a significant portion of TAM through the increasing adoption of regenerative medicine products.
Upturn SWOT Analysis
Strengths
- Innovative RECELL technology
- Rapid skin regeneration capabilities
- Reduced donor site requirements
- Clinical evidence supporting efficacy
Weaknesses
- Reliance on a single product line
- Limited market penetration compared to larger players
- High cost of initial investment for hospitals
- Regulatory hurdles for expansion into new markets
Opportunities
- Expansion into new wound care applications
- Partnerships with hospitals and clinics
- Geographic expansion into emerging markets
- Development of next-generation RECELL technology
Threats
- Competition from established wound care companies
- Development of alternative skin regeneration technologies
- Changes in reimbursement policies
- Product liability risks
Competitors and Market Share
Key Competitors
- MDT
- BSX
- JNJ
Competitive Landscape
Avita Medical holds a competitive advantage due to its unique RECELL technology. However, it faces strong competition from larger companies with established market presence and broader product portfolios.
Growth Trajectory and Initiatives
Historical Growth: Avita Medical Ltd's growth has been driven by increasing adoption of the RECELL device and expansion into new markets.
Future Projections: Future growth is projected to come from expanded product applications, increased market penetration, and geographic expansion.
Recent Initiatives: Recent strategic initiatives include securing regulatory approvals in new regions and expanding the sales force.
Summary
Avita Medical Ltd shows promise in regenerative medicine with its innovative RECELL technology. While its growth is notable, it is crucial to expand product applications and strengthen market presence. The company must navigate competition and regulatory hurdles to secure sustainable long-term success. Management should leverage ReceLL to continue sales growth and improve operating efficiency.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Website
- Analyst Reports
- Industry Publications
Disclaimers:
This analysis is based on publicly available information and should not be considered financial advice. Market conditions are subject to change.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Avita Medical Ltd
Exchange NASDAQ | Headquaters Valencia, CA, United States | ||
IPO Launch date 2019-10-01 | CEO, President & Executive Director Mr. James M. Corbett | ||
Sector Healthcare | Industry Medical Devices | Full time employees 260 | Website https://avitamedical.com |
Full time employees 260 | Website https://avitamedical.com | ||
AVITA Medical, Inc., together with its subsidiaries, operates as a therapeutic acute wound care company in the United States, Japan, the European Union, Australia, and the United Kingdom. The company's lead product is the RECELL System, a cell harvesting device used for the treatment of thermal burn wounds and full-thickness skin defects, as well as for repigmentation of stable depigmented vitiligo lesions. It also provides RECALL autologous cell harvesting device, which can treat areas of up to 1,920 cm2; RECELL autologous cell harvesting device with ease-of-use, an enhanced ease-of-use device that can treat areas of up to 1,920 cm²; and RECELL GO mini autologous cell harvesting device, a line extension of the RECELL GO system to treat smaller wounds up to 480 cm2, as well as RECELL GO autologous cell harvesting device consisting of RECELL GO processing device, which controls and manages the pressure applied to disaggregate the donor skin cells and controls the incubation time of the RECELL Enzyme to optimize cell yield and promote cell viability; and RECELL GO preparation kit, which can treat areas up to 1,920 cm2. In addition, the company markets, sells, and distributes PermeaDerm, a biosynthetic wound matrix; and Cohealyx, a collagen-based dermal matrix. It serves hospitals, treatment centers, and distributors. The company was formerly known as AVITA Therapeutics, Inc. and changed its name to AVITA Medical, Inc. in December 2020. AVITA Medical, Inc. is headquartered in Valencia, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.